These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
925 related articles for article (PubMed ID: 32859638)
1. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. Chevallier M; Tsantoulis P; Addeo A; Friedlaender A Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638 [TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer. Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341 [TBL] [Abstract][Full Text] [Related]
4. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Ludovini V; Bianconi F; Pistola L; Pistola V; Chiari R; Colella R; Bellezza G; Tofanetti FR; Siggillino A; Baldelli E; Flacco A; Giuffrida D; Sidoni A; Crinò L Cancer Chemother Pharmacol; 2012 May; 69(5):1289-99. PubMed ID: 22302407 [TBL] [Abstract][Full Text] [Related]
5. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627 [TBL] [Abstract][Full Text] [Related]
7. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations. Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
9. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202 [TBL] [Abstract][Full Text] [Related]
10. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866 [TBL] [Abstract][Full Text] [Related]
11. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders. Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677 [TBL] [Abstract][Full Text] [Related]
12. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714 [TBL] [Abstract][Full Text] [Related]
13. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations. Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study. Wang X; Zeng Z; Cai J; Xu P; Liang P; Luo Y; Liu A BMC Cancer; 2021 Apr; 21(1):482. PubMed ID: 33931014 [TBL] [Abstract][Full Text] [Related]
16. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy. Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819 [TBL] [Abstract][Full Text] [Related]
17. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study. Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152 [TBL] [Abstract][Full Text] [Related]
18. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC. Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717 [TBL] [Abstract][Full Text] [Related]
19. Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance. Zheng J; Dou Y; Huang D; Wang Y; Han R; Hu C; Zhu M; Lu C; Lin C; Wu D; Liu Y; Tang H; He T; Jiang W; He Y Jpn J Clin Oncol; 2024 Jan; 54(1):89-96. PubMed ID: 37721193 [TBL] [Abstract][Full Text] [Related]
20. Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Lim SM; Kim HR; Cho EK; Min YJ; Ahn JS; Ahn MJ; Park K; Cho BC; Lee JH; Jeong HC; Kim EK; Kim JH Oncotarget; 2016 Jun; 7(24):36311-36320. PubMed ID: 27121209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]